Ciluprevir

Ciluprevir is a protease inhibitor used in the treatment of hepatitis C. It is a peptidomimetic agent that inhibits the NS3/4A serine protease of the hepatitis C virus, preventing viral replication.

Mechanism of Action[edit | edit source]

Ciluprevir works by binding to the NS3/4A serine protease of the hepatitis C virus, inhibiting its function. This enzyme is essential for the replication of the virus, as it is involved in the processing of the viral polyprotein, a precursor to the individual proteins that make up the virus. By inhibiting this enzyme, Ciluprevir prevents the virus from replicating and spreading.

Pharmacokinetics[edit | edit source]

After oral administration, Ciluprevir is rapidly absorbed and extensively distributed throughout the body. It is metabolized primarily by the liver, with the majority of the drug excreted in the feces.

Side Effects[edit | edit source]

Common side effects of Ciluprevir include fatigue, headache, and nausea. Less common but more serious side effects can include liver damage, severe skin reactions, and anemia.

Drug Interactions[edit | edit source]

Ciluprevir can interact with a number of other medications, including other protease inhibitors, certain antiviral medications, and some types of cholesterol-lowering drugs. It is important for patients to inform their healthcare provider of all medications they are currently taking to avoid potential drug interactions.

Clinical Trials[edit | edit source]

Ciluprevir has been studied in several clinical trials for its efficacy in treating hepatitis C. These trials have shown that the drug can be effective in reducing viral load and improving liver function in patients with this disease.